NCT03179033 is a clinical trial in Artificial Heart Device User, sponsored by Sheba Medical Center.

Who is sponsoring NCT03179033?

NCT03179033 is sponsored by Sheba Medical Center.

What condition does NCT03179033 study?

NCT03179033 studies Artificial Heart Device User.

Is NCT03179033 still recruiting?

NCT03179033 is currently completed. Last updated 18 January 2018.

Last reviewed 2018-01-18 · How we verify

NCT03179033

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Impact of Fluid and Passive Leg Raising on Cardiac Output in Patients Undergoing Cardiac Surgery

Completed Last updated 18 January 2018

What this trial tests

trial in Artificial Heart Device User in 20 participants. Completed in 30 August 2017.

Timeline

19 October 2016

Primary endpoint
30 August 2017

30 August 2017

Quick facts

Lead sponsor	Sheba Medical Center
Status	Completed
Study type	OBSERVATIONAL
Enrollment	20
Start date	19 October 2016
Primary completion	30 August 2017
Estimated completion	30 August 2017
Sites	1 location across Israel

Conditions studied

Artificial Heart Device User — all drugs for Artificial Heart Device User →

Sponsor

Sheba Medical Center

Who can join

18 and older, any sex, with Artificial Heart Device User. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Left Ventricular Assist Device (LVAD) implantation is a common surgical procedure in patients with end-stage heart failure. Optimal fluid management is essential for adequate postoperative treatment. It is important to identify which patients will benefit from fluid administration. Passive leg raising (PLR) is a validated dynamic method to predict fluid responsiveness in patients with heart failure by inducing a transient increase in cardiac preload. Objective: To investigate the role of PLR on the management of patients following LVAD implantation in the postoperative period.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Sheba Medical Center trials

Trials by the same sponsor.

NCT07401524 — Carbetocin Uterotonic Treatment in Twin Pregnancies for Prevention of Postpartum Hemorrhage · Phase 4 · not yet recruiting
NCT07523373 — Facial Nerve Monitoring During Parotid and Facial Surgery Using a Non-Invasive Patch · NA · not yet recruiting
NCT07509229 — 9-cis Beta-Carotene-Rich Extract of Dunaliella Alga in Retinitis Pigmentosa Patients · Phase 1, PHASE2 · not yet recruiting
NCT07405723 — Arm Position and Blood Pressure Measurement Accuracy During Pregnancy · NA · recruiting
NCT07474987 — Portable VR-based Chromatic Pupilloperimeter for Diagnosis and Monitoring of Traumatic Brain Injury · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03179033 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sheba Medical Center
Last refreshed: 18 January 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03179033.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing